Related Experiment Video
Updated: Mar 16, 2026
Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer
Y-H Taguchi1, Mitsuo Iwadate2, Hideaki Umeyama2
1Department of Physics, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, 112-8551, Tokyo, Japan. tag@granular.com.
Background:
Non-small cell lung cancer (NSCLC) remains a lethal disease despite many proposed treatments. Recent studies have indicated that epigenetic therapy, which targets epigenetic effects, might be a new therapeutic methodology for NSCLC. However, it is not clear which objects (e.g., genes) this treatment specifically targets. Secreted frizzled-related proteins (SFRPs) are promising candidates for epigenetic therapy in many cancers, but there have been no reports of SFRPs targeted by epigenetic therapy for NSCLC.
Methods:
This study performed a meta-analysis of reprogrammed NSCLC cell lines instead of the direct examination of epigenetic therapy treatment to identify epigenetic therapy targets. In addition, mRNA expression/promoter methylation profiles were processed by recently proposed principal component analysis based unsupervised feature extraction and categorical regression analysis based feature extraction.
Results:
The Wnt/β-catenin signalling pathway was extensively enriched among 32 genes identified by feature extraction. Among the genes identified, SFRP1 was specifically indicated to target β-catenin, and thus might be targeted by epigenetic therapy in NSCLC cell lines. A histone deacetylase inhibitor might reactivate SFRP1 based upon the re-analysis of a public domain data set. Numerical computation validated the binding of SFRP1 to WNT1 to suppress Wnt signalling pathway activation in NSCLC.
Conclusions:
The meta-analysis of reprogrammed NSCLC cell lines identified SFRP1 as a promising target of epigenetic therapy for NSCLC.
Insights
Secreted frizzled-related protein 1 (SFRP1) is identified as a potential epigenetic therapy target for non-small cell lung cancer (NSCLC). This finding suggests SFRP1 may reactivate suppressed Wnt signaling pathways, offering a new therapeutic avenue for NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge.
- Epigenetic therapy is emerging as a potential treatment strategy for NSCLC.
- Specific molecular targets for epigenetic therapy in NSCLC remain largely undefined.
Purpose of the Study:
- To identify potential molecular targets for epigenetic therapy in NSCLC.
- To investigate the role of secreted frizzled-related proteins (SFRPs) in NSCLC epigenetic therapy.
Main Methods:
- A meta-analysis was conducted on reprogrammed NSCLC cell lines.
- Unsupervised feature extraction methods, including principal component analysis and categorical regression, were applied to mRNA expression and promoter methylation profiles.
Main Results:
- The Wnt/β-catenin signaling pathway was significantly enriched among 32 identified genes.
- SFRP1 was identified as a key gene targeting β-catenin, suggesting its potential role in NSCLC.
- Re-analysis of public data indicated that a histone deacetylase inhibitor could reactivate SFRP1.
- Numerical computations confirmed SFRP1's binding to WNT1, suppressing Wnt signaling in NSCLC.
Conclusions:
- SFRP1 is a promising molecular target for epigenetic therapy in NSCLC.
- Targeting SFRP1 could offer a novel therapeutic strategy for managing NSCLC.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
